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InitiationlPromotion Versus Complete
Carcinogenicity in the Rodent Liver
by John Ashby,* B. M. Elliott,* P. A. Lefevre,*
Jerry Styles* and E. Longstaff*
4-N-Pyrrolidinylazobenzene (4N) is a close structural analog of the rodent liver carcinogen 4-di-
methylaminoazobenzene (DAB). This structural similarity led us to evaluate it for genotoxic activity
in vitro. We observed activity for 4N and DAB in the BHK cell transformation assay and subse-
quently in the Salmonella mutation assay of Ames. By a curious chance, Scribner, Miller and Miller,
probably prompted by the same structural similarity, had synthesized 4N in the 1960s and found it
to be noncarcinogenic to the rodent liver using a bioassay test protocol that detected DAB as carci-
nogenic. These findings were only described following the publication of our observations made in
vitro.
The conflict that apparently exists between these data can be interpreted in two separate ways.
(a) Scribner et al. have suggested that 4N may be a carcinogenic initiator as opposed to a complete
carcinogen like DAB. They also suggested that promotion of 4N-treated rodents with phenobarbi-
tone might lead to the production of liver tumors. (b) We have evaluated the simpler concept that
the activities observed for 4N in vitro define a carcinogenic potential that is not realized in vivo
due to its rapid detoxification, at least in rodents.
The first of these explanations implies that pure carcinogenic initiators may form a separate
class of genotoxic agents from complete carcinogens, and perhaps of greater interest, that 4N might
provide a valuable model compound for the study of carcinogenic promotion in the rodent liver. The
second explanation regards potential carcinogenicity as a single property that can be defined in
vitro and which may or may not be expressed in vivo depending on the enzymic environments en-
countered by the test chemical. It is clearly important to evaluate these different propositions in
order to aid progress in the study of carcinogenic promotion, especially in the rodent liver. The
presentation will describe our recent studies in vitro and in vivo in this connection.
Introduction
Dramatic progress has been made during the
past decade in both our understanding of the mode
of action of organic chemical carcinogens and in the
development of techniques for their detection. It is
now generally accepted that an initiating event is
induced in the nucleus of somatic cells by reaction
of the carcinogen with DNA. Using this as a start-
ing point, it is now possible to discern chemicals ca-
pable of such reactions using one or more bacterial
or mammalian cell mutation assays. The fact that
the majority of organic carcinogens give a positive
response in such assays has led to various laws in
several countries aimed at regulating the use of
new chemicals found positive in these assays. This
assumed equivalence of mutation in vitro and car-
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cinogenicity in vivo has fostered a perhaps decep-
tively simple approach to the control of environmen-
tal carcinogens.
The legislative initiatives referred to above, to-
gether with the attendant battery of short-term
tests that these laws require, take no account of the
possible modulation of the carcinogenic expression
of compound A by concomitant exposure of the host
animal to chemicals B, C, etc. The significance of
this omission is illustrated by the fact that several
modulating agents are known that either enhance
or attenuate the 'degree' of carcinogenicity of some
carcinogens but which are themselves neither muta-
genic nor carcinogenic. The several modulating ef-
fects produced by the noncarcinogenic nonmutagen
disulfiram illustrate this concern (1, 2).
The present symposium is concerned with carci-
nogenic promotion, i.e., the effect of chemical B on
the carcinogenicity of chemical A. This "promotion"
can take the form of either an increase in the ob-ASHBYETAL.
served tumor yield expected of a given dose of the
carcinogen or a reduction in the latent period re-
quired to produce the original tumor yield. A major
obstacle to a rational approach to the study of car-
cinogen promoting agents is that although, almost
without exception, these agents are nonmutagenic
in vitro, most have been shown to be weakly carci-
nogenic to rodents. Thus, not only are the promot-
ing properties of such agents hard to anticipate in
the absence of animal bioassays, but their "carcino-
genicity" is not correlated with mutagenic activity
in vitro.
It is suggested by several authors elsewhere
herein that the carcinogenicity to the mouse liver of
liver promoting agents such as phenobarbitone,
DDT or dieldrin, may simply provide evidence of
their ability to promote pre-existing and preneoplas-
tic lesions in that organ. The species and strain spe-
cificity of the carcinogenicity, but not the promoting
properties of these agents supports this suggestion.
If these suggestions are confirmed, complete (i.e.,
initiating and self-promoting) carcinogens and pure
promoting agents will form two discrete groups of
xenobiotics. In anticipation of this possible resolu-
tion, consideration of a third class of agent, pure ini-
tiators, forms the basis of this paper. The relation-
ship between pure initiation and pure promotion
(both noncarcinogenic events) and complete carcino-
genicity and initiation/promotion (both carcinogenic
events) is shown (Fig. 1).
Evidence Supporting the Existence
of Noncarcinogenic Initiating
Agents
The majority of carcinogen promoting studies
employ a low dose-level of an established carcinogen
as the initiating agent and subsequent repeated ad-
ministration of a promoting agent. The test proto-
cols are usually so adjusted that neither the initiat-
ing agent nor the promoting agent alone produces
tumors within the time course of the study; the car-
cinogenic effects observed are therefore the clear
product of initiation/promotion. Higher dose levels
of the initiating agent are carcinogenic without aux-
iliary promotion, and most of these agents are ac-
tive in short-term tests such as the Salmonella mu-
tation assay of Ames (3,4). This coincidence of activ-
ities has led to the general assumption that a chemi-
cal found to be active in an established in vitro
assay is potentially able both to initiate the carcino-
genic sequence, and, at appropriate dose levels, to
produce tumors.
Contrary to this assumption, several instances of
putative noncarcinogens showing activity in in vitro
mutagenicity assays, but not in short-term assays
conducted in vivo have recently been encountered.
Several such instances were observed in a recent
publication (4) as illustrated by the contrasting test
profiles of the carcinogen 2-acetylaminofluorene (2-
SCHEME I
FIGURE 1. Relationships between carcinogenic initiation/promotion and complete carcinogenicity. The existence of pure initiating
agents and noncarcinogenic (i.e., pure) promoting agents is speculative and forms the basis of the present discussion.
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AAF) and its putatively noncarcinogenic 4-sub-
stituted analog 4-AAF (Fig. 2).
The immediate question posed by these findings
is whether the mutagenic noncarcinogen 4-AAF
may be effective as an initiating agent but be inca-
pable of promoting itself. This would coincide with
the present definition of a pure initiating agent.
This conclusion cannot be drawn at present due to
the paucity of the available negative carcinogenicity
data. A related example from our own researches
(6) is illustrated by the similar mutagenicities in
vitro of the potent liver carcinogen 6-dimethyl-
aminophenylazobenzthiazole (6BT) and the apparent
noncarcinogen 5-dimethylaminophenylazoindazole
(51) (Fig. 3).
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A further possible example of a pure initiating
agent has been suggested by Scribner et al. (8),
namely, 4-N-pyrrolidinylazobenzene (4N). We have
demonstrated (9) that this structural analog of the
rodent liver carcinogen DAB is active in both the
BHK cell transformation (10) and Salmonella muta-
tion assays (Fig. 4). DAB gives a positive response
in each of these assays (7, 12; data not shown). How-
ever, Scribner et al. (8) have shown that 4N is inac-
tive in a limited rodent carcinogenicity bioassay
that concurrently detected DAB as positive. Simi-
larly, 2-methyl-4-dimethylaminoazobenzene (2M) is
known to bind covalently to hepatic DNA, RNA and
protein (13) but not to produce tumors in that organ
(14). If however, the treated animals are subse-
quently promoted with phenobarbitone, tumors are
produced (14).
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The above examples provide evidence in favor of
the concept that some bacterial mutagens may be
capable of initiating preneoplastic events within the
nucleus of somatic cells but be incapable themselves
of promoting these lesions-they therefore appear
to be noncarcinogenic and could consequently be re-
ferred to as pure initiating agents.
The immediacy of the need for studies designed
to explore the possible existence of a discrete class
of noncarcinogenic initiating agents is illustrated by
the weight of evidence currently in favor of their
existence, and by the influence that they would
have, if adequately defined, on the study of carcino-
gen promotion (cf. the unresolved assumptions im-
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FIGURE 2. Comparison of the gross genotoxicity profiles of 2-acetylaminofluorene (2-AAF) and its 4-acetylamino isomer (4-AAF).
The mutagenic dose-response curve observed for each chemical (+ S9) in Salmonella is derived from the data submitted by
Trueman to the International Study (4). The mouse micronucleus in vivo assay data were similarly submitted to that study by
Salamone et al. and Tschuchimoto et al. These two chemicals were recently evaluated independently by Nashed etal.(5) in their
rat peritoneal macrophage assay, a positive and negative response being observed, respectively, as shown. The carcinogenicity
classifications were as used in the International Study (4) and are discussed in more detail therein by Purchase et al. (Chapter
4).
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FIGURE 3. Mutagenic activity (6) of 6-dimethylaminophenylazobenzthiazole (6BT) and 5-dimethylaminophenylazoindazole (5D) when
evaluated in S. typhimurium (strain TA98) using a pre-incubation assay (7) and Aroclor 1254-induced rat liver S9 mix.
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FIGURE 4. Positive response (9) observed for 4-N-pyrrolidinylazobenzene (4N) in the BHK cell transformation assay (10) and the
Salmonella mutation assay (11) (strain TA 98, pre-incubation test'0). Both experiments were conducted in the presence of an
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plicit in Figure 1). However, this evidence, espe-
cially that relating to the alleged noncarcinogenicity
of such agents, must first be carefully assessed, as
attempted below.
Assessment of the Evidence in
Favor of the Existence of Pure
Initiating Agents
The most important variable in initiation/promo-
tion studies is the dose level at which the initiating
carcinogen is administered. The level selected is
usually the highest that will not, in the absence of
promotion, produce a significant increase in cancer
incidence within the time course of the study. But
the fact that higher dose levels of the same agent
are able to produce a carcinogenic response clearly
defines the critical importance of the dosimetry in
these studies. Within this context, the credibility
that can be accorded to a candidate for pure initiat-
ing agent is inexorably linked to the dose levels at
which it has been evaluated for carcinogenicity.
This is a particularly important consideration be-
cause, until recently, chemicals were typically as-
sayed for carcinogenicity via administration to be-
tween 10 and 50 rats followed by only a limited his-
topathological assessment of their major organs.
Further, these studies were often terminated after
only 1 year of exposure to the chemical. Such meth-
ods, while adequate for detection of "potent" carcin-
ogens, are insufficient to define noncarcinogenicity,
but their implicit use for this purpose in the past
suggests that a proportion of the chemicals cur-
rently regarded as being "noncarcinogenic" may ac-
tually be weak carcinogens (6).
In the case of the three azo compounds men-
tioned earlier, i.e., 6BT (17), 5I (18) and 4N (8), the
carcinogenicity bioassays were conducted at a sin-
gle dose level, which in the case of the two noncar-
cinogens, are shown herein to be only a fraction of
their maximum tolerated dose (MLD) level (Table 1).
A comparison of the published carcinogenicity
data on 6BT, 5I and 4N with their relative toxicities
as observed in our laboratory is shown in Figure 5.
The substantial differences in the relative toxicity
of both 4N and 5I to the carcinogen 6BT reflects ad-
versely upon the reliability of their classification as
noncarcinogens. In particular, the probable fact that
the "noncarcinogenicity" of these compounds was
established at only r\4O4% of their maximum tole-
rated dose (MTD) should be viewed within the con-
text that many established carcinogens prove inac-
tive when tested at such reduced dose-levels and for
so short a period of time (cf. the basis for conducting
initiation/promotion studies).
The true carcinogenic status of 4N and 5I can
only be determined via further bioassays conducted
at higher dose levels and for longer periods of time,
however, an analysis of the short-term (1-6 week) ef-
fects they produce in rodents may indicate the like-
ly outcome of such studies (see below and Table 2).
Biological Profile of 4N
This material failed to affect significantly the rate
of growth of the test animals up to dose levels of
500 mg/kg over a period of 6 weeks (Fig. 6). In addi-
tion, the livers of the treated rats were normal in
terms of pathology and nuclear ploidy (cf. Table 2
for 6BT and 5I). Further, evaluation of cellular pro-
tein for covalent addition of 4N gave negative re-
sults at the 2-week and 6-week points. In contrast to
these negative findings, the spleens of the treated
animals were enlarged and their blood levels of
methaemoglobin elevated (>8% compared to control
levels of <1%). These findings are consistent with
the rapid cleavage of 4N in vivo (either in the gut or
in the liver) to yield aniline a known methemoglobi-
nemic agent (23) and rodent spleen carcinogen (24).
-=\ /=\
AZOREDUCTION
N=N N\ NH2
4 N Aniline
These data therefore suggest that 4N is unlikely
to be a rodent liver carcinogen at any dose level.
However, the effects seen in the spleen suggest
Table 1. Comparison of published data on 6BT, 51 and 4N.a
Dose level MTD Estimated factor of MTD at
Activity Carcinogenicity administered, in AP rats via which bioassay Predicted carcinogenicity
Chemical in vitro (SD rats) % in diet gavage, mg/kg conducted at MTD
6BT + + 0.03 \ 7.5 rv100% +
5I + - 0.03 -'200 \ 40% +
4N + - 0.06 >500 < 3% -
a The carcinogenicity bioassay data for 6BT and 5I in Sprague Dawley (SD) rats are from Brown et al. (17, 18) while those for 4N
are from Scribner et al. (8). The studies in Alderley Park (AP) rats will be described by us in detail elsewhere (11). MTD = maximum
tolerated dose by daily stomach gavage ofa single bolus in corn oil.
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FIGURE 5. Composite data derived in rats for 6BT, 4N and 5I. The lower axis of each histogram represents previous observations
made by Brown et al. (17, 18) for 6BT and 5I and Scribner et al. (8) for 4N, each derived from bioassays in which the test
chemicals were administered via the diet. The top axis of each histogram represents the data obtained in our laboratory (11),
doses being expressed as mg/kg via gavage. The correspondence between the MTD of 6BT ("-7.5mg/kg) in the present study
and 0.03% in diet in the study of Brown et al. (17) has been used to calibrate the remainder of the histograms. Doses shown in
parentheses are estimated based on observations made in the complementary study (cf. complementary axis). Use of the word
"toxic" implies observation of moribund animals or recorded deaths. "Subtoxic" doses do not, therefore, preclude cellular
changes induced in the liver. The potent hepatotoxicity and hepatocarcinogenicity of 6BT has been confirmed in this laboratory
by using both the gavage and dietary routes and both SD and AP rats (11).
Table 2. Comparative activities of 6BT, 5I and 4N, administered via gavage, in the livers of Alderly Park rats.a
Evidence of pre-
MTD in AP Evidence of Reduction in Evidence of neoplastic changes
rats (mg/kg, Effects on covalent addition relative proportion mitotic activity in the liver
Chemical gavage) body weight to protein of tetraploid nuclei in liver (oval cells, etc.)
6BT "-7.5 + b + + +
5I "-'200 + + + + +
4N >500 - -
a All determinations were made within the first 4 weeks of dosing. The nuclear ploidy determinations (based themselves on the
findings of Neal and Butler (19) were made using a flow cytometer and will be published elsewhere (20). The liver histopathology
(mitotic activity and H & E section analysis) will also be discussed elsewhere (11). The dye-binding experiments were determined
optically by using the method of Miller and Miller (11, 21).
b The failure to detect protein-bound dye may be associated with the low dose levels employed; further studies are in progress.
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Biological Profile of 2M
This chemical has apparently good credentials as
I / l a pure initiating agent: it binds to hepatic nuclear
DNA and RNA after oral administration to rats but
fails to produce liver tumors. These findings are
nonetheless subject to at least two restraints. First,
the dose level employed in the carcinogenicity bio-
assay of 2M by Kitagawa et al. (14) (the standard
0.06% in diet) was not related to its MTD. Second,
G"=N-O"O
Roe et al.(15) have provided limited evidence of the
carcinogenicity of this chemical to the mouse liver.
4N A further and more detailed carcinogenicity bio-
assay of 2M is therefore required before it can be
* Control classed as a pure initiating agent. This material has
o 4N 500 mg/kg/ day not been studied in our laboratory, thus it does not
figure in Tables 1 and 2; however, appropriate ex-
20 24 28 periments with it are planned.
DAYS
FIGURE 6. Growth curves for control(- 0 -) and 4N-treated
(- O -) male Alderly Park rats over the first 4 weeks of
treatment. Each data point represents the average of five
animals (+ SD). No deaths occurred during this ex-
periment. The rv5% depression in body weight between
the treated and control groups at 28 days was derived by
comparison of means.
that the induction of cancer by 4N in this organ can-
not be excluded. Such an effect, if established,
would probably be associated with the secondary
toxicity and not with the primary potential (liver)
carcinogenicity discerned for this chemical by struc-
tural considerations and the activities observed for
it in vitro. Further, we suggest that it is unlikely
that 4N will even prove to be an initiating agent in
the rodent liver. In particular, no evidence of any
change in the liver was discerned at the elevated
dose level of 500 mg/kg.
Biological Profile of 51
The hepatic effects observed for this chemical at
"-'200 mg/kg (Table 2) suggest that it may prove car-
cinogenic to the liver at these dose levels. These
changes included histopathological disturbances
similar to those seen in the preneoplastic phase of
the azo dye-induced carcinogenicity (16), a reduc-
tion in the tetraploid component of the hepatic nu-
clei and covalent addition of the test chemical to cel-
lular protein. These findings suggest that the re-
ported noncarcinogenicity of this material may be
an illusion created by the low dose levels employed
(rv4% of the MTD level) and the short duration (8
months) of the only available carcinogenicity bio-
assay, and consequently, that it is unlikely to be de-
fined ultimately as a pure (i.e., noncarcinogenic) initi-
ating agent.
Conclusions
The search for a noncarcinogenic initiating agent
is made attractive by the order it would bring to
carcinogen promotion studies. However, the candi-
date examples currently available are insecurely
based due to the inadequacy of their carcinogenicity
bioassay data. This conclusion is not based solely on
the examples discussed herein; pyrene, methyl
orange, a-naphthylamine, dinitrosopentamethylene-
tetramine and 3-methyl-4-nitroquinoline N-oxide
have been similarly classified (4). The issue of pure
initiators is, however, of sufficient philosophical im-
portance for it to be pursued even if it is finally es-
tablished that as a class they do not exist. The evi-
dence currently available suggests that the bac-
terial mutagens that have so far proven to be non-
carcinogenic to rodents are either rapidly detoxified
in vivo, and are therefore incapable of reaching the
target organ of interest in high enough dose levels
to initiate preneoplastic lesions (e.g., 4N?), or that
they only appear to be non-carcinogenic because
they have not been adequately tested for carcino-
genicity (e.g., 5I?). Appropriate studies on 4N and 5I
are currently in hand in these laboratories to an-
swer these questions for these particular com-
pounds. In the meantime, initiation/promotion stud-
ies will have to employ low dose levels of a com-
plete carcinogen as the initiating species (16).
NOTE ADDED IN PROOF: The bacterial
mutagenicity of 4N has subsequently been
published (25).
The technical assistance of Liz Riley, Neville Pritchard and
David Hart is gratefully acknowledged. Artwork was pro-
vided by the late John Madden. The assessment of the
histopathology of the livers of the treated animals was un-
dertaken by Dr. M. Robinson.
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